• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Malarone (atovaquone; proguanil hydrochloride) Tablet

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Malarone (atovaquone; proguanil hydrochloride) Tablet

  • Profile

Profile

Contact Information

Contact: GlaxoSmithKline
Website: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Malarone/pdf/MALARONE.PDF

Currently Enrolling Trials

    Show More

    General Information

    Malarone is a fixed-dose combination of atovaquone and proguanil hydrochloride, antimalarial agents.

    Malarone is specifically indicated for:

    • prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported
    • treatment of acute, uncomplicated P. falciparum malaria

    Malarone is supplied as tablets. The daily dose should be taken at the same time each day with food or a milky drink. In the event of vomiting within 1 hour after dosing, a repeat dose should be taken. Malarone may be crushed and mixed with condensed milk just prior to administration to patients who may have difficulty swallowing tablets.

    Prevention of Malaria

    Start prophylactic treatment with Malarone 1 or 2 days before entering a malaria-endemic area and continue daily during the stay and for 7 days after return.

    • Adults: One Malarone tablet (adult strength = 250 mg atovaquone/100 mg proguanil hydrochloride) per day.
    • Pediatric Patients: The dosage for prevention of malaria in pediatric patients is based upon body weight seen below:
    Weight (kg) Atovaquone/ Proguanil HCl Total Daily Dose Dosage Regimen
    11-20 62.5 mg/25 mg 1 Malarone pediatric tablet daily
    21-30 125 mg/50 mg 2 Malarone pediatric tablets as a single daily dose
    31-40 187.5 mg/75 mg 3 Malarone pediatric tablets as a single daily dose
    >40 250 mg/100 mg 1 Malarone tablet (adult strength) as a single daily dose

     

    Treatment of Acute Malaria

    • Adults: Four Malarone tablets (adult strength; total daily dose 1 g atovaquone/400 mg proguanil hydrochloride) as a single daily dose for 3 consecutive days.
    • Pediatric Patients: The dosage for treatment of acute malaria in pediatric patients is based upon body weight seen below:
    Weight (kg) Atovaquone/ Proguanil HCl Total Daily Dose Dosage Regimen
    5-8 125 mg/50 mg 2 Malarone pediatric tablets daily for 3 consecutive days
    9-10 187.5 mg/75 mg 3 Malarone pediatric tablets daily for 3 consecutive days
    11-20 250 mg/100 mg 1 1 Malarone tablet (adult strength) daily for 3 consecutive days
    21-30 500 mg/200 mg 2 Malarone tablets (adult strength) as a single daily dose for 3 consecutive days
    31-40 750 mg/300 mg 3 Malarone tablets (adult strength) as a single daily dose for 3 consecutive days
    >40 1 g/400 mg 4 Malarone tablets (adult strength) as a single daily dose for 3 consecutive days

     

    Mechanism of Action

    The constituents of Malarone, atovaquone and proguanil hydrochloride, interfere with two different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a dihydrofolate reductase inhibitor. Inhibition of dihydrofolate reductase in the malaria parasite disrupts deoxythymidylate synthesis.

    Side Effects

    Side effects which may occur in adult patients include, but are not limited to:

    • abdominal pain
    • nausea
    • vomiting
    • headache
    • diarrhea
    • asthenia
    • dizziness
    • anorexia

    Side effects which may occur in pediatric patients include, but are not limited to:

    • nausea
    • vomiting
    • pruritus

    Clinical Trial Results

    Three phase II clinical studies were conducted, one testing atovaquone alone, one testing proguanil hydrochloride alone and one testing the combination, for the treatment of acute, uncomplicated malaria. Malarone was tested in eight phase III controlled clinical trials for the same indication. 471 patients were treated with the equivalent of four Malarone tablets once daily for three days. 464 had a sensitive response (the elimination of parasitemia with no recurrent sign of parasitemia for up to 28 days) and seven patients had R1 resistance (the elimination of parasitemia, but with recurrence between 7 and 28 days following treatment). Treatment with Malarone was comparable with treatment with a comparator drug in four of the studies and better than treatment with a comparator drug in the other four studies. The overall efficacy in 521 patients was 98.7%.

    Approval Date: 2000-07-01
    Company Name: GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 25Apr

      Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

    • 26Apr

      FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

    • 27Apr

      Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

    • 17May

      2023 WCG Avoca Quality Consortium Summit

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • tablet

      Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

    • Diversity-360x240.png

      Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

    • Five Ws

      Consider the Five ‘W’s to Understand Potential Participants

    • QandA-360x240.png

      Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing